variant

stratum

≤224

225 - 253

≥254

P-value

N = 425

N = 11

N = 89

Age (M ± SD)

61.9 ± 0.6

64.7 ± 2.2

63.1 ± 12.9

0.529

Gender (n, %)

Male

229

70.4%

10

90.9%

62

69.7%

0.327

Female

126

29.6%

1

9.1%

27

30.3%

TMN Stage

I

158

37.3%

3

27.3%

13

14.8%

0.001*

II

89

21.0%

0

0.0%

7

8.0%

III

127

30.0%

7

63.6%

51

58.0%

IV

50

11.8%

1

9.1%

17

19.3%

Differentiation (Diff) (n, %)

well

15

3.5%

0

0.0%

3

3.4%

0.001*

moderately

84

19.8%

2

18.2%

12

13.5%

poorly

19

4.5%

0

0.0%

3

3.4%

Un-Diff

0

0.0%

1

9.1%

0

0.0%

unknown

307

72.2%

8

72.7%

71

79.8%

Hepatitis B/C (n, %)

Non B/C

68

16.0%

2

20.0%

26

29.2%

0.121

HBV

194

45.6%

4

40.0%

36

40.4%

HCV

147

34.6%

3

30.0%

25

28.1%

HBV + HCV

16

3.8%

1

10.0%

2

2.2%

GOT (M ± SD)

77.8 ± 3.8

55 ± 10.5

101.8 ± 9.3

0.021*

GPT (M ± SD)

63 ± 3.1

46.2 ± 13.3

56.9 ± 5.3

0.482

GOT/GPT (M ± SD)

1.40 ± 0.05

1.65 ± 0.62

2.25 ± 0.20

0.001*

Albumin (M ± SD

3.6 ± 0.0

3.8 ± 0.2

3.3 ± 0.1

0.001*

WBC × 10³ (M ± SD)

7.0 ± 0.2

7.8 ± 1.2

9.5 ± 0.6

0.001*

Platalate × 10³ (M ± SD)

143.9 ± 3.3

221.9 ± 32.9

280.1 ± 12.4

0.001*

Neutrophi (M ± SD)

4697.1 ± 181

6131.1 ± 1107

7972.6 ± 543.2

0.001*

Lymphocyte (M ± SD)

1474.5 ± 40.3

903.6 ± 129.8

713 ± 41.2

0.001*

Treat. method

Non-surgical

312

73.4%

8

72.7%

74

83.1%

0.153

Surgical

113

26.6%

3

27.3%

15

16.9%

Survive

Death

286

67.3%

7

63.6%

80

89.9%

0.001*

Alive

139

32.7%

4

36.4%

9

10.1%